PAVM - PAVmed Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.9520
-0.0379 (-3.83%)
As of 1:48PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.9899
Open0.9900
Bid0.9712 x 900
Ask0.9724 x 900
Day's Range0.9520 - 0.9900
52 Week Range0.8600 - 1.4000
Volume70,673
Avg. Volume209,112
Market Cap33.378M
Beta (3Y Monthly)0.55
PE Ratio (TTM)N/A
EPS (TTM)-0.6470
Earnings DateSep 5, 2019 - Sep 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents

    Edited Transcript of PAVM earnings conference call or presentation 5-Sep-19 8:30pm GMT

    Q2 2019 PAVmed Inc Earnings Call

  • GlobeNewswire

    PAVmed Reports Second Quarter 2019 Financial Results and Provides Business Update

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for the three and six months ended June 30, 2019 and provided a business update. “The second quarter and early third quarter has been a period of solid progress for PAVmed,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer. “We advanced our lead product portfolio on multiple fronts, including the recent successful completion of all procedures in the CarpX™ clinical safety study.

  • GlobeNewswire

    USPTO Grants PAVmed Patent Covering its CarpX™ Device

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 10,335,189 which covers the technology underlying PAVmed’s CarpX minimally invasive device developed to treat carpal tunnel syndrome. “We believe this patent creates significant barriers to entry for current and future competitors in the minimally invasive and percutaneous carpal tunnel release space, and will provide us with the commercial freedom to operate as we pursue the billion-dollar U.S. market opportunity that CarpX represents.

  • GlobeNewswire

    PAVmed Successfully Completes Clinical Safety Study Procedures for CarpX™ 510(k) Re-submission

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that all 20 patients of its first-in-human (FIH) 510(k) clinical safety study underwent successful CarpX procedures. The study is being conducted to support PAVmed’s planned 510(k) re-submission to the U.S. Food and Drug Administration (FDA) seeking marketing clearance of its CarpX minimally invasive carpal tunnel release device. “We are excited to have achieved this critical milestone,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer.

  • GlobeNewswire

    PAVmed to Hold Business Update Conference Call on September 5, 2019

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will file its SEC 10-Q quarterly report on or before the August 14, 2019 deadline, report second quarter 2019 financial results on or before September 5, 2019 and host a conference call on Thursday, September 5, 2019 at 4:30 p.m. Eastern time. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will provide a business update including an overview of the Company’s near-term milestones and growth strategy.

  • What Kind Of Shareholder Appears On The PAVmed Inc.'s (NASDAQ:PAVM) Shareholder Register?
    Simply Wall St.

    What Kind Of Shareholder Appears On The PAVmed Inc.'s (NASDAQ:PAVM) Shareholder Register?

    Every investor in PAVmed Inc. (NASDAQ:PAVM) should be aware of the most powerful shareholder groups. Generally...

  • GlobeNewswire

    PAVmed to Join Russell Microcap® Index

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced the Company is set to join the Russell Microcap® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the U.S. market opens on July 1, according to a preliminary list of additions posted on June 7, 14 and 21. FTSE Russell determines membership for its Russell indexes primarily by objective, market capitalization rankings and style attributes. “We are pleased that PAVmed will be included in the Russell Microcap® Index,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer.

  • GlobeNewswire

    PAVmed Subsidiary Lucid Diagnostics Receives FDA 510(k) Clearance for EsoCheck™

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product medical device company, today announced that its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), has received 510(k) marketing clearance for its EsoCheck Cell Collection Device™ (“EsoCheck”) from the U.S. Food and Drug Administration (FDA). “I have spent my career seeking to improve the care of patients with gastroesophageal reflux disease and Barrett’s Esophagus and to prevent deaths from esophageal cancer.

  • Thomson Reuters StreetEvents

    Edited Transcript of PAVM earnings conference call or presentation 21-May-19 8:30pm GMT

    Q1 2019 PAVmed Inc Earnings Call

  • GlobeNewswire

    PAVmed Reports First Quarter 2019 Financial Results and Provides Business Update

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for the three months ended March 31, 2019 and provided a business update.

  • GlobeNewswire

    PAVmed Announces First Human CarpX™ Procedures

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the first group of nine patients with carpal tunnel syndrome underwent successful CarpX procedures as part of the first-in-human (FIH) clinical safety study PAVmed is conducting in support of its planned U.S. Food and Drug Administration (FDA) 510(k) re-submission. “Simply stated, CarpX works.

  • GlobeNewswire

    PAVmed to Hold Business Update Conference Call on May 21, 2019

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will report first quarter 2019 financial results on or before May 21, 2019 and host a conference call on Tuesday, May 21, 2019 at 4:30 p.m. Eastern time. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennis McGrath, the Company’s Chief Financial Officer, will discuss first quarter 2019 financial results.

  • GlobeNewswire

    PAVmed Reports Excellent DisappEAR™ Animal Study Results

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its DisappEAR™ resorbable pediatric ear tube achieved a major developmental milestone with the successful completion of a 90-day study in an established animal model to support a planned U.S. Food and Drug Administration (FDA) 510(k) submission later this year. “First, the resorbable ear tubes, machined from blocks of a proprietary silk technology, performed very well from a functional and anatomic point of view, retaining their position and remaining patent for the duration of the study. Christopher J. Hartnick, M.D., Professor of Otolaryngology at Harvard Medical School and Chief of Pediatric Otolaryngology at Massachusetts Eye and Ear Infirmary and Massachusetts General Hospital, performed the study.

  • GlobeNewswire

    PAVmed Announces Registered Direct Offering of its Common Stock

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has entered into agreements for the sale of 1,655,000 shares of common stock in a registered direct offering at a price of $1.00 per share. The estimated net proceeds to PAVmed from the registered direct offering are expected to be approximately $1.6 million after deducting the placement agent’s fees and other estimated offering expenses. Maxim Group LLC is acting as the exclusive placement agent with respect to certain institutional investors for this offering.

  • Investors Who Bought PAVmed (NASDAQ:PAVM) Shares A Year Ago Are Now Down 32%
    Simply Wall St.

    Investors Who Bought PAVmed (NASDAQ:PAVM) Shares A Year Ago Are Now Down 32%

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! PAVmed Inc. (NASDAQ:PAVM) shareholders should be happy to see the share price up 17% in the last month. But that doesn...

  • GlobeNewswire

    PAVmed Reports Fourth Quarter 2018 Financial Results and Provides Business Update

    NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) --  PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today reported financial results for the three and 12 months ended December 31, 2018 and provided a business update.

  • GlobeNewswire

    PAVmed to Hold Business Update Conference Call on April 4, 2019

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will report fourth quarter 2018 financial results on or before April 4, 2019 and host a conference call on Thursday, April 4, 2019 at 4:30 p.m. Eastern time. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennis McGrath, the Company’s Chief Financial Officer, will discuss fourth quarter 2018 financial results.

  • GlobeNewswire

    PAVmed Announces NextFlo™ Breakthrough

    Groundbreaking disposable gravity-driven intravenous (IV) infusion set achieves flow accuracy comparable to expensive electronic infusion pumps, independent of IV bag height. NEW YORK, March 20, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its NextFlo™ Infusion System (“NextFlo”) achieved a key milestone in its quest to eliminate the need for complex and expensive electronic infusion pumps for most of the estimated 1 million infusions of fluids, medications and other substances delivered each day in hospitals and outpatient settings in the United States. NextFlo is a completely disposable intravenous (IV) infusion set designed to deliver highly-accurate gravity-driven infusions independent of the height of the IV bag.

  • GlobeNewswire

    PAVmed Announces PortIO™ Breakthrough

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its PortIO™ Intraosseous Infusion System, which consists of an implantable intraosseous vascular access device and insertion kit, was able to achieve a maintenance-free implant duration of over 60 days in pre-clinical animal testing. Former President of the Society of Interventional Radiology (SIR), Timothy P. Murphy, M.D., described this announcement as “a truly groundbreaking accomplishment in the field of vascular access which, if replicated in clinical practice, would represent one of the most important advances in long-term vascular access that I have seen during my career.

  • GlobeNewswire

    PAVmed Subsidiary Lucid Diagnostics Launches World-Class Medical Advisory Board and Appoints Chief Medical Officer

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product medical device company, today announced that its subsidiary, Lucid Diagnostics Inc. (“Lucid”), has launched a world-class medical advisory board (MAB) consisting of internationally renowned experts in gastroesophageal reflux disease (GERD), Barrett’s Esophagus (BE) and esophageal cancer and has appointed veteran life sciences industry executive David Wurtman, MD, MBA, as its Chief Medical Officer.

  • GlobeNewswire

    PAVmed Provides Business Update

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided an update on its business. “I am pleased to report that PAVmed’s 2019 is off to an excellent start with continued progress as we approach multiple value-creating milestones,” said Lishan Aklog M.D., PAVmed’s Chairman and CEO. “With CarpX’s first-in-human (FIH) 510(k) clinical safety study in process, EsoCheck CCD’s 510(k) application in the interactive review phase and EsoCheck Dx’s Laboratory Developed Test (LDT) designation imminent, a full business update seems warranted.

  • ACCESSWIRE

    Stonegate Capital Partners Initiates Coverage on PAVmed, Inc. (PAVM)

    PAVmed, Inc. (PAVM) is a highly differentiated multi-product medical device company that focuses on developing high-margin, single-use products for interventional or acute care. The Company's product pipeline includes CarpX™, a percutaneous device for the treatment of carpal tunnel syndrome, EsoCheck™, a non-invasive device and DNA biomarker assay test to detect an esophageal cancer precursor, PortIO™, an implantable intraosseous vascular access device, DisappEAR™, an antimicrobial resorbable ear tube, and NextFlo™, a highly accurate disposable infusion system, in addition to several other candidates.

  • How Much Money Does PAVmed Inc (NASDAQ:PAVM) Make?
    Simply Wall St.

    How Much Money Does PAVmed Inc (NASDAQ:PAVM) Make?

    If you are currently a shareholder in PAVmed Inc (NASDAQ:PAVM), or considering investing in the stock, you need to examine how the business generates cash, and how it is reinvested. Read More...